Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVC-COV1901 as a 3rd boost after ChAdOx1-nCov-19
NCT05097053Phase 4Unknown
- Sponsor
- Taoyuan General Hospital
- Start
- Oct 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of MVC-COV1901 in coronavirus disease 2019 (COVID-19), sponsored by Taoyuan General Hospital. Status: unknown.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05097053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097053.